ライフサイエンスコーパス: haemolytic

1 Significantly higher levels of haemolytic activity (approximately 16-fold) were observe

2 lysing (lecithinase) activity, 1.5 times the haemolytic activity and over seven times the activity to

3 nce of both the major secreted protein and a haemolytic activity from the mutant signalled that the L

4 EF demonstrated that it is CylE that confers haemolytic activity in E. coli.

5 tein of Borrelia burgdorferi by means of its haemolytic activity in Escherichia coli.

6 Haemolytic activity in the mutant laboratory strains cou

7 fic lipase that contributes to lipolytic and haemolytic activity in vitro and is required for optimal

8 es tested, H. pinifolia recorded the minimum haemolytic activity of 2.07+/-0.63% at 1000 mug/ml conce

9 ffect on enzymatic activity, it inhibits the haemolytic activity of PlcHR2.

10 580) failed to prevent the contact-dependent haemolytic activity of Shigella.

11 of band 3 function significantly reduced the haemolytic activity of streptolysin S, and dramatically

12 Phe69Cys substitutions markedly reduced the haemolytic activity of the enzyme, our work suggests tha

13 Enhanced haemolytic activity of the luxS strain was also shown to

14 Remarkably, LukSF-PV inhibition of LukED haemolytic activity on both human and murine erythrocyte

15 The haemolytic activity was erythrocyte-species specific, wi

16 The haemolytic activity was shown to be highly protease sens

17 s in cylB, cylF and cylH retaining wild-type haemolytic activity were identified in all strains.

18 response to growth phase, including enhanced haemolytic activity, and a dramatic reduction in the exp

19 e third class had nearly wild-type levels of haemolytic activity, but had a decrease in protein half-

20 strain, designated 35000-3, lacks detectable haemolytic activity.

21 The first class had a severe defect in haemolytic activity.

22 ytotoxic (brine shrimp leathality assay) and haemolytic activity.

23 In addition, Cyt toxins also display haemolytic activity.

24 agA in group G streptococcus eliminated beta-haemolytic activity.

25 genetic basis for group G streptococcus beta-haemolytic activity.

26 e protein which stabilized BlyA and enhanced haemolytic activity.

27 The fibronectin/fibrinogen-binding/haemolytic-activity/streptokinase-regulator-X (FasX) sRN

28 encoding gene fibronectin/fibrinogen-binding/haemolytic-activity/streptokinase-regulator-X (fasX) wer

29 5% of patients) being pyrexia and autoimmune haemolytic anaemia (seven [7%] each), pneumonia (six [6%

30 Further all the patients with chronic haemolytic anaemia and alcoholic cirrhosis had black pig

31 cretion of 5-oxoproline, metabolic acidosis, haemolytic anaemia and central nervous system damage.

32 ive longer, the chronic effects of sustained haemolytic anaemia and episodic vaso-occlusive events dr

33 opment beginning at about 9 months of severe haemolytic anaemia and several malignant cancers, both o

34 to be clinically important, protect against haemolytic anaemia in hepatitis-C-infected patients rece

35 ations in PIEZO1 cause an autosomal dominant haemolytic anaemia in humans called dehydrated hereditar

36 is erythrocyte age and dose-dependent acute haemolytic anaemia in individuals with glucose-6-phospha

37 erocytosis (HS) is the most common inherited haemolytic anaemia in Northern Europeans.

38 The haemolytic anaemia is characterized by an increase in er

39 ominant role of complement in disease is the haemolytic anaemia of paroxysmal nocturnal haemoglobinur

40 did not have refractory disease, autoimmune haemolytic anaemia requiring treatment, chronic or activ

41 active hepatitis B or C infection; or active haemolytic anaemia were excluded.

42 There was less haemolytic anaemia with fludarabine plus cyclophosphamid

43 n ratio, ineffective erythropoiesis, chronic haemolytic anaemia, compensatory haemopoietic expansion,

44 Repeated sickling and ongoing haemolytic anaemia, even when subclinical, lead to paren

45 Clinically, this disease manifests as haemolytic anaemia, thrombocytopenia, and renal insuffic

46 zed by thrombocytopenia and microangiopathic haemolytic anaemia, was almost universally fatal until t

47 f the most important of these is RBV-induced haemolytic anaemia, which affects most patients and is s

48 ted to erythrocytes and only associated with haemolytic anaemia.

49 rocytic red blood cell morphology and severe haemolytic anaemia.

50 t not Ppara(-/-) mice from PHZ-induced acute haemolytic anaemia.

51 ap mutations associated with non-spherocytic haemolytic anaemia.

52 erization, in membrane insertion and also in haemolytic and insecticidal activities.

53 ted integrations in cylE were invariably non-haemolytic and non-cytolytic, a finding confirmed by in

54 The haemolytic/cytolytic activity of the cylE allelic exchan

55 Genetic analysis of the haemolytic determinant revealed two borrelia haemolysin

56 , and subsequent prevention of Rhesus (Rh) D haemolytic disease of the fetus and newborn, is the most

57 e has significantly reduced the incidence of haemolytic disease of the foetus and newborn previously

58 t, a non-acylated, enzymatically active, non-haemolytic form of AC toxin is able to increase cAMP, re

59 nts with underlying medical conditions, beta-haemolytic group G streptococcus can produce necrotising

60 beta-haemolytic group G streptococcus was the sole microbial

61 crotising soft tissue infections due to beta-haemolytic group G streptococcus.

62 Group A streptococcus (GAS), a beta-haemolytic human pathogen, expresses a NEAT protein, Shr

63 i, and a transformant was identified as beta-haemolytic on blood agar.

64 The beta-haemolytic phenotype of group G streptococcus is produce

65 he long-standing mystery of the variable non-haemolytic phenotype of its immediate parent, RN450.

66 We show here that the non-haemolytic phenotype of RN4220 is caused by an extra A r

67 issociation between agr activity and the non-haemolytic phenotype of RN4220, and has solved the long-

68 eptolysin S (SLS) produces the hallmark beta-haemolytic phenotype produced by GAS.

69 investigated a potential link of shared beta-haemolytic phenotype to disease pathogenesis.

70 - and delta-haemolysins, and hence, in a non-haemolytic phenotype.

71 site, demonstrated attenuated lipolytic and haemolytic phenotypes when compared with the isogenic pa

72 old purification and characterization of the haemolytic phospholipase C (PLC) of Pseudomonas aerugino

73 aperone PlcR2 affects both the enzymatic and haemolytic properties of PlcH.

74 Haemolytic risk is dependent on treatment dose and patie

75 Their haemolytic risk when treated with 8-aminoquinolines has

76 orm a national-level index of relative G6PDd haemolytic risk.

77 , together with a national index of relative haemolytic risk.

78 ably higher predictive power of drug induced haemolytic risk.

79 coding the CylA and CylB system by the alpha-haemolytic S. gordonii is presented.

80 mediated illnesses secondary to group A beta-haemolytic streptococcal infections present with motor a

81 Cw6 and environmental triggers, such as beta-haemolytic streptococcal infections, are major determina

82 beta-haemolytic streptococci from all positive cultures were

83 with pharyngitis, 107 (24%) had group A beta-haemolytic streptococci on throat culture.

84 corded and a throat culture for group A beta-haemolytic streptococci was done.

85 may occur after infection with group A beta-haemolytic streptococci.

86 Haemolytic titres, total PlcH protein and beta-galactosi

87 e of eculizumab in the treatment of atypical haemolytic uraemic syndrome (aHUS) as well as the other

88 Most cases of diarrhoea-associated haemolytic uraemic syndrome (HUS) are caused by Shiga-to

89 Haemolytic uraemic syndrome (HUS), which is caused by Sh

90 The largest number of adult cases of haemolytic uraemic syndrome (HUS)/thrombotic thrombocyto

91 c E. coli isolates, including the historical haemolytic uraemic syndrome (HUSEC) E. coli HUSEC041 O10

92 and the treatment of shiga toxin associated haemolytic uraemic syndrome (STEC HUS) is also provided.

93 their proximity to conserved basic residues, haemolytic uraemic syndrome may result from a failure of

94 sed the large 2011 outbreak of diarrhoea and haemolytic uraemic syndrome secretes blended virulence f

95 The outbreak of diarrhoea and haemolytic uraemic syndrome that occurred in Germany in

96 non-bloody diarrhoea, haemorrhagic colitis, haemolytic uraemic syndrome, and death.

97 udies suggest that treatment may precipitate haemolytic uraemic syndrome, and other studies suggest n

98 icant, number of infected people develop the haemolytic uraemic syndrome, which is the most frequent

99 to lessen the risk of the development of the haemolytic uraemic syndrome.

100 istribution of mutations leading to atypical haemolytic uraemic syndrome.

101 ses diarrhoea, haemorrhagic colitis, and the haemolytic uraemic syndrome.

102 between SCR-16 to SCR-20 is associated with haemolytic uraemic syndrome.

103 some of which included fatalities caused by haemolytic uraemic syndrome.

104 sual numbers of cases of bloody diarrhoea or haemolytic uraemic syndrome.

105 ntified in a clinical isolate in which a non-haemolytic variant had arisen during the course of infec

106 ically heterogeneous in storage, and its non-haemolytic variants had the 8A mutation.

107 homology to SlyA, originally thought to be a haemolytic virulence determinant in Salmonella typhimuri